JSH-23

JSH-23 is an inhibitor of NF-κB transcriptional activity with IC50 of 7.1 μM. (In Vitro) :JSH-2 (1-300 μM; 24 hours) at <100 μM does not show significant cytotoxic effects on the RAW 264.7 cells.Nuclear amount of NF-κB p65 is markedly increased upon exposure to LPS for 1 h. Treatment of JSH-23 (30 μM; 1 hours) to LPS- stimulated RAW 264.7 cells decreases nuclear content of NF-κB p65 in a dose-dependent manner. (In Vivo) :JSH-23 (1 mg/kg, 3 mg/kg; orally administered; daily; for 2 weeks) significantly reverses the nerve conduction and nerve blood flow deficits seen in diabetic rats.